Table 4 Antihypertensives and statins: genes with variants that potentially affect the drug response rate or the risk of adverse side effects
From: Application of personalized medicine to chronic disease: a feasibility assessment
Drug name | Brand name | Pharmacogenetic genes | PubMed ID | Effect |
|---|---|---|---|---|
ACE inhibitors | ||||
Captopril | Capoten | AGTR1 | 18347611 | Specific variants (s.v.) associated with improved outcomes |
Enalapril | Vasotec; Renitec | |||
Ramipril | Altace; Tritace; | |||
Perindopril | Coversyl; Aceon | AGTR1; BDKRB1 | 20712529; 20712529 | S.v. associated with improved outcomes |
Lisinopril | Listril; Lopril; Novatec; | AGTR1; CLCN6; NPPA | 18347611; 18212314 | S.v. associated with improved outcomes |
AGTR2 antagonists | ||||
Losartan | Cozaar; Hyzaar; Lacidipine; Lortaan | CYP2C9 | 11823761; 11408373 | CYP2C9*3 allele is associated with a reduced rate of drug metabolism |
Irbesartan | Avalide; Avapro; Irbesarran; | APOB; LDLR | 15453913; 15453913 | S.v. associated with improved outcomes |
Candesartan | Amias; Atacand; Blopress; | KNG1 | 19584173 | S.v. associated with improved outcomes |
Valsartan | Diovan | |||
Telmisartan | Micardis; Pritor | |||
Statins | ||||
Atorvastatin | Lipitor; Torvast | CYP3A4; ABCB1; HTR7;HTR3B; GNB3; USP5; SLCO1B1; ABCC1 | 17600820; 18851956; 19833260; 18851956 | Risk or phenotype-associated alleles |
Rosuvastatin | Crestor | CYP2C8; CYP2C19 | 20178046 | |
Simvastatin | Zocor; Lipex | CYP3A4; HCR; SLCO1B1; AGTR1; KIF6; HTR7; HTR3B; GNB3; USP5; ITGB3; | 11250978; 20403997; 18073581; 18551043; 18222353; 18222354; 18222355; 17600820; 11545752 | Risk or phenotype-associated alleles |